Abstract

Background and PurposeTo evaluate the inter-observer variation (IOV) in pharyngeal constrictor muscle (PCM) contouring, and resultant impact on dosimetry and estimated toxicity, as part of the pre-trial radiotherapy trial quality assurance (RTQA) within DARS, a multicenter phase III randomized controlled trial investigating the functional benefits of dysphagia-optimized intensity-modulated radiotherapy (Do-IMRT) in pharyngeal cancers.Methods and MaterialsOutlining accuracy of 15 clinicians’ superior and middle PCM (SMPCM) and inferior PCM (IPCM) were retrospectively assessed against gold standards (GS) using volume, location, and conformity indices (CIs) on a pre-trial benchmark case of oropharyngeal cancer. The influence of delineation variability on dose delivered to the constrictor muscles with Do-IMRT and resultant normal tissue complication probability (NTCP) for physician-scored radiation-associated dysphagia at 6 months was evaluated.ResultsFor GS, SMPCM, and IPCM volumes were 13.51 and 1.67 cm3; corresponding clinician mean volumes were 12.18 cm3 (SD 3.0) and 2.40 cm3 (SD 0.9) respectively. High IOV in SMPCM and IPCM delineation was observed by the low DICE similarity coefficient value, along with high geographical miss index and discordance index values. Delineation variability did not significantly affect the mean dose delivered to the constrictors, relative to the GS plan. Mean clinician NTCP was 24.6% (SD 0.6), compared to the GS-NTCP of 24.7%.ConclusionsResults from this benchmark case demonstrate that inaccurate PCM delineation existed, even with protocol guidelines. This did not impact on delivered dose to this structure with Do-IMRT, or on estimated swallowing toxicity, in this single benchmark case.

Highlights

  • Irradiation of the pharyngeal constrictor muscle (PCM) is implicated with post-radiotherapy (RT) dysphagia in head and neck cancer (HNC), resulting in increased risks of aspiration, prolonged feeding tube dependency, and worsened health-related quality of life [1, 2]

  • There was a comprehensive section on PCM delineation, which was based on the guidelines by Christianen et al [6], and the slice-by-slice contouring atlas produced by the PATHOS radiotherapy trial quality assurance (RTQA) team [7]

  • The Geographical miss index (GMI) values indicated that a mean of 6.3 cm3 and 0.5 cm3 of the gold standard (GS)– superior and middle PCM (SMPCM) and –inferior PCM (IPCM) contours were outside the clinicians’ outlining respectively

Read more

Summary

Introduction

Irradiation of the pharyngeal constrictor muscle (PCM) is implicated with post-radiotherapy (RT) dysphagia in head and neck cancer (HNC), resulting in increased risks of aspiration, prolonged feeding tube dependency, and worsened health-related quality of life [1, 2]. DARS (CRUK/14/014) is a phase III randomized controlled trial in the UK that is currently investigating the functional benefits of reducing dose to the constrictors with dysphagia-optimized intensity-modulated RT (Do-IMRT), relative to standard IMRT, in cancers of the oropharynx and hypopharynx [3]. To evaluate the inter-observer variation (IOV) in pharyngeal constrictor muscle (PCM) contouring, and resultant impact on dosimetry and estimated toxicity, as part of the pre-trial radiotherapy trial quality assurance (RTQA) within DARS, a multicenter phase III randomized controlled trial investigating the functional benefits of dysphagia-optimized intensity-modulated radiotherapy (Do-IMRT) in pharyngeal cancers

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call